Stay updated on Pegcetacoplan in ALS Adults: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the Pegcetacoplan in ALS Adults: Efficacy & Safety Clinical Trial page.

Latest updates to the Pegcetacoplan in ALS Adults: Efficacy & Safety Clinical Trial page
- Check3 days agoChange DetectedThe record presents the MERIDIAN Phase 2 trial of pegcetacoplan for ALS, including its termination after missing the primary and key secondary efficacy endpoints, while reporting tolerability consistent with the established safety profile. It also provides the trial design, outcomes, eligibility criteria, locations, and study documents.SummaryDifference75%

- Check10 days agoChange DetectedA site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check17 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating access to the study record is blocked and the usual study details are replaced by an error screen. The header and navigation reflect an error page rather than the study content.SummaryDifference18%

- Check66 days agoChange DetectedRevision: v3.6.6 replaces the previous Revision: v3.6.5, indicating a deployment update. No core page content or study information is changed.SummaryDifference0.1%

Stay in the know with updates to Pegcetacoplan in ALS Adults: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegcetacoplan in ALS Adults: Efficacy & Safety Clinical Trial page.